Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581212 | 0.89 | MET (0.66) | METNQO2MEN1KMT2A | |
| SCHEMBL1581279 | 0.89 | MET (0.53) | METNQO2 | |
| SCHEMBL1581374 | 0.83 | MET (0.55) | METNQO2 | |
| SCHEMBL15132639 | 0.83 | MET (0.49) | METNQO2 | |
| SCHEMBL1581220 | 0.82 | MET (0.50) | METNQO2 | |
| SCHEMBL12720594 | 0.81 | MET (0.48) | METNQO2 | |
| SCHEMBL1581481 | 0.81 | MET (0.72) | METNQO2 | |
| SCHEMBL1581330 | 0.81 | MET (0.59) | METNQO2 | |
| SCHEMBL13152862 | 0.80 | MET (0.60) | METNQO2MEN1KMT2A | |
| SCHEMBL13099326 | 0.80 | MET (0.59) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859547-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | claimed |
| US-8557813-B2 | 2-benzylpyridazinone derivatives as met kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-20130190311-A1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-07-25 | — | — | US | claimed |
| EP-2220070-B1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-04-20 | — | — | EP | claimed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | claimed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| US-8859547-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859547-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859547-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8557813-B2 | 2-benzylpyridazinone derivatives as met kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557813-B2 | 2-benzylpyridazinone derivatives as met kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| EP-2220070-B1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2220070-B1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2220070-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | Merck Patent GmbH (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009083076-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009083076-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | ERBB2, RET, MET | MET 3/4885NQO2 822/4885MEN1 637/4885 |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | MET 592/4885NQO2 64/4885MEN1 314/4885 |
| US-20130190311-A1 | Pyridazinone derivatives | MET, RET, ERBB2 | MET 1/4885NQO2 603/4885MEN1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.